A Role for LHC1 in Higher Order Structure and Complement Binding of the Cryptococcus neoformans Capsule

PLoS Pathogens

Volumn 10, Issue 5, 2014, Pages

  Park, Yoon Dong ^a   Shin, Soowan ^b   Panepinto, John ^c   Ramos, Jeanie ^b   Qiu, Jin ^a   Frases, Susana ^d,e   Albuquerque, Patricia ^d   Cordero, Radames J B ^d   Zhang, Nannan ^a   Himmelreich, Uwe ^f   Beenhouwer, David ^g,h   Bennett, John E ^a   Casadevall, Arturo ^d   Williamson, Peter R ^a,b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; HYDROLASE; PROTEIN BINDING;

ANIMAL; CELL CULTURE; CHEMISTRY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FUNGAL CAPSULE; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; MOUSE; NUCLEAR MAGNETIC RESONANCE; PATHOGENICITY; PHYSIOLOGY; PROTEOMICS; ULTRASTRUCTURE; VIRULENCE;

ANIMALS; CELLS, CULTURED; COMPLEMENT SYSTEM PROTEINS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FUNGAL CAPSULES; HUMANS; HYDROLASES; MICE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN BINDING; PROTEOMICS; VIRULENCE;

EID: 84901647434     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1004037     Document Type: Article

References (60)

1. Roberts IS, Saunders FK, Boulnois GJ, (1989) Bacterial capsules and interactions with complement and phagocytes. Biochem Soc Trans 17: 462-464.
2. Horwitz MA, Silverstein SC, (1980) Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes. J Clin Invest 65: 82-94.
3. Schneider MC, Exley RM, Ram S, Sim RB, Tang CM, (2007) Interactions between Neisseria meningitidis and the complement system. Trends Microbiol 15: 233-240.
4. Vecchiarelli A, (2000) Immunoregulation by capsular components of Cryptococcus neoformans. Med Mycol 38: 407-417.
5. Kisenge PR, Hawkins AT, Maro VP, McHele JP, Swai NS, et al. (2007) Low CD4 count plus coma predicts cryptococcal meningitis in Tanzania. BMC Infect Dis 7: 39.
6. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, et al. (2009) Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. Aids 23: 525-530.
7. Kumar P, Yang M, Haynes BC, Skowyra ML, Doering TL, (2011) Emerging themes in cryptococcal capsule synthesis. Curr Opin Struct Biol 21: 597-602.
8. Cherniak R, Sundstrom JB, (1994) Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect Immun 62: 1507-1512.
9. Doering TL, (2009) How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in Cryptococcus neoformans. Annu Rev Microbiol 63: 223-247.
10. Cordero RJ, Frases S, Guimaraes AJ, Rivera J, Casadevall A, (2011) Evidence for branching in cryptococcal capsular polysaccharides and consequences on its biological activity. Mol Microbiol 79: 1101-1117.
11. Goren MB, Middlebrook GM, (1967) Protein conjugates of polysaccharide from Cryptococcus neoformans. J Immunol 98: 901-913.
12. Rodrigues ML, Nakayasu ES, Oliveira DL, Nimrichter L, Nosanchuk JD, et al. (2008) Extracellular vesicles produced by Cryptococcus neoformans contain protein components associated with virulence. Eukaryot Cell 7: 58-67.
13. Kataoka M, Yamamoto K, Shimizu S, Ohta M, Kita A, et al. (1998) Crystallization and preliminary X-ray diffraction study of lactonohydrolase from Fusarium oxysporum. Acta Crystallogr D Biol Crystallogr 54: 1432-1434.
14. Malik A, Firoz A, Jha V, Ahmad S, (2010) PROCARB: A Database of Known and Modelled Carbohydrate-Binding Protein Structures with Sequence-Based Prediction Tools. Adv Bioinformatics pp. 436036.
15. Svensson C, Teneberg S, Nilsson CL, Kjellberg A, Schwarz FP, et al. (2002) High-resolution crystal structures of Erythrina cristagalli lectin in complex with lactose and 2′-alpha-L-fucosyllactose and correlation with thermodynamic binding data. J Mol Biol 321: 69-83.
16. Bicanic T, Harrison TS, (2004) Cryptococcal meningitis. Br Med Bull 72: 99-118.
17. Shimizu S, Kataoka M, Shimizu K, Hirakata M, Sakamoto K, et al. (1992) Purification and characterization of a novel lactonohydrolase, catalyzing the hydrolysis of aldonate lactones and aromatic lactones, from Fusarium oxysporum. Eur J Biochem 209: 383-390.
18. Casellas M, Grifoll M, Bayona JM, Solanas AM, (1997) New metabolites in the degradation of fluorene by Arthrobacter sp. strain F101. Appl Environ Microbiol 63: 819-826.
19. Zhu X, Gibbons J, Garcia-Rivera J, Casadevall A, Williamson PR, (2001) Laccase of Cryptococcus neoformans is a cell wall-associated virulence factor. Infect Immun 69: 5589-5596.
20. Janbon G, Himmelreich U, Moyrand F, Improvisi L, Dromer F, (2001) Cas1p is a membrane protein necessary for the O-acetylation of the Cryptococcus neoformans capsular polysaccharide. Mol Microbiol 42: 453-467.
21. Gates MA, Thorkildson P, Kozel TR, (2004) Molecular architecture of the Cryptococcus neoformans capsule. Mol Microbiol 52: 13-24.
22. Fonseca FL, Nimrichter L, Cordero RJ, Frases S, Rodrigues J, et al. (2009) Role for chitin and chitooligomers in the capsular architecture of Cryptococcus neoformans. Eukaryot Cell 8: 1543-1553.
23. Frases S, Pontes B, Nimrichter L, Viana NB, Rodrigues ML, et al. (2009) Capsule of Cryptococcus neoformans grows by enlargement of polysaccharide molecules. Proc Natl Acad Sci U S A 106: 1228-1233.
24. Muller RH, Jacobs C, Kayser O, (2001) Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47: 3-19.
25. Zhang S, Hacham M, Panepinto J, Hu G, Shin S, et al. (2006) The Hsp70 member, Ssa1 acts as a DNA-binding transcriptional co-activator in Cryptococcus neoformans. Mol Microbol 62: 1090-1101.
26. Wang X, Wang P, Sun S, Darwiche S, Idnurm A, et al. (2012) Transgene induced co-suppression during vegetative growth in Cryptococcus neoformans. PLoS Genet 8: e1002885.
27. De Jesus M, Chow SK, Cordero RJ, Frases S, Casadevall A, (2010) Galactoxylomannans from Cryptococcus neoformans varieties neoformans and grubii are structurally and antigenically variable. Eukaryot Cell 9: 1018-1028.
28. Mukherjee J, Nussbaum G, Scharff MD, Casadevall A, (1995) Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med 181: 405-409.
29. Feldmesser M, Kress Y, Novikoff P, Casadevall A, (2000) Cryptococcus neoformans is a facultative intracellular pathogen in murine pulmonary infection. Infect Immun 68: 4225-4237.
30. Taborda CP, Casadevall A, (2002) CR3 (CD11b/CD18) and CR4 (CD11c/CD18) are involved in complement-independent antibody-mediated phagocytosis of Cryptococcus neoformans. Immunity 16: 791-802.
31. Kozel TR, (1993) Opsonization and phagocytosis of Cryptococcus neoformans. Arch Med Res 24: 211-218.
32. Kozel TR, Wilson MA, Murphy JW, (1991) Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect Immun 59: 3101-3110.
33. Mershon-Shier KL, Vasuthasawat A, Takahashi K, Morrison SL, Beenhouwer DO, (2011) In vitro C3 deposition on Cryptococcus capsule occurs via multiple complement activation pathways. Mol Immunol 48: 2009-2018.
34. Kozel TR, Pfrommer GS, (1986) Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast. Infect Immun 52: 1-5.
35. Panepinto J, Liu L, Ramos J, Zhu X, Valyi-Nagy T, et al. (2005) The DEAD-box RNA helicase Vad1 regulates multiple virulence-associated genes in Cryptococcus neoformans. J Clin Invest 115: 632-641.
36. Shapiro S, Beenhouwer DO, Feldmesser M, Taborda C, Carroll MC, et al. (2002) Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect Immun 70: 2598-2604.
37. Casadevall A, Perfect J (1998) Cryptococcus neoformans. Wash D.C.: ASM Press.
38. Cherniak R, Valafar H, Morris LC, Valafar F, (1998) Cryptococcus neoformans chemotyping by quantitative analysis of 1H nuclear magnetic resonance spectra of glucuronoxylomannans with a computer-simulated artificial neural network. Clin Diagn Lab Immunol 5: 146-159.
39. Fevrier B, Raposo G, (2004) Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol 16: 415-421.
40. Shimizu S, Kataoka M, Honda K, Sakamoto K, (2001) Lactone-ring-cleaving enzymes of microorganisms: their diversity and applications. J Biotechnol 92: 187-194.
41. Nilsson L, Leeman M, Wahlund KG, Bergenstahl B, (2006) Mechanical degradation and changes in conformation of hydrophobically modified starch. Biomacromolecules 7: 2671-2679.
42. Murakami T, Uchida S, Ishizu K, (2008) Architecture of hyperbranched polymers consisting of a stearyl methacrylate sequence via a living radical copolymerization. J Colloid Interface Sci 323: 242-246.
43. Nimrichter L, Frases S, Cinelli LP, Viana NB, Nakouzi A, et al. (2007) Self-aggregation of Cryptococcus neoformans capsular glucuronoxylomannan is dependent on divalent cations. Eukaryot Cell 6: 1400-1410.
44. McFadden DC, De Jesus M, Casadevall A, (2006) The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction. J Biol Chem 281: 1868-1875.
45. McFadden DC, Fries BC, Wang F, Casadevall A, (2007) Capsule structural heterogeneity and antigenic variation in Cryptococcus neoformans. Eukaryot Cell 6: 1464-1473.
46. Zaragoza O, Telzak A, Bryan RA, Dadachova E, Casadevall A, (2006) The polysaccharide capsule of the pathogenic fungus Cryptococcus neoformans enlarges by distal growth and is rearranged during budding. Mol Microbiol 59: 67-83.
47. Chun CD, Liu OW, Madhani HD, (2007) A link between virulence and homeostatic responses to hypoxia during infection by the human fungal pathogen Cryptococcus neoformans. PLoS Pathog 3: e22.
48. Diamond RD, May JE, Kane M, Frank MM, Bennett JE, (1973) The role of late complement components and the alternate complement pathway in experimental cryptococcosis. Proc Soc Exp Biol Med 144: 312-315.
49. Mershon KL, Vasuthasawat A, Lawson GW, Morrison SL, Beenhouwer DO, (2009) Role of complement in protection against Cryptococcus gattii infection. Infect Immun 77: 1061-1070.
50. Diamond RD, May JE, Kane MA, Frank MM, Bennett JE, (1974) The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J Immunol 112: 2260-2270.
51. Zhu X, Williamson PR, (2004) Role of laccase in the biology and virulence of Cryptococcus neoformans. FEMS Yeast Res 5: 1-10.
52. Williamson PR, (1994) Biochemical and molecular characterization of the diphenol oxidase of Cryptococcus neoformans: identification as a laccase. J Bacteriol 176: 656-664.
53. Merkel GJ, Scofield BA, (1994) Comparisons between in vitro glial cell adherence and internalization of non-encapsulated and encapsulated strains of Cryptococcus neoformans. J Med Vet Mycol 32: 361-372.
54. Moyrand F, Klaproth B, Himmelreich U, Dromer F, Janbon G, (2002) Isolation and characterization of capsule structure mutant strains of Cryptococcus neoformans. Mol Microbiol 45: 837-849.
55. Duus J, Gotfredsen CH, Bock K, (2000) Carbohydrate structural determination by NMR spectroscopy: modern methods and limitations. Chem Rev 100: 4589-4614.
56. Erickson T, Liu L, Gueyikian A, Zhu X, Gibbons J, et al. (2001) Multiple virulence factors of Cryptococcus neoformans are dependent on VPH1. Mol Microbiol 42: 1121-1131.
57. Cox G, Mukherjee J, Cole G, Casadeval lA, Perfect J, (2000) Urease as a virulence factor in experimental cryptococcosis. Infect Immun 68: 443-448.
58. Liu L, Wakamatsu K, Ito S, Williamson PR, (1999) Catecholamine oxidative products, but not melanin, are produced by Cryptococcus neoformans during neuropathogenesis in mice. Infect Immun 67: 108-112.
59. Salas SD, Bennett JE, Kwon-Chung KJ, Perfect JR, Williamson PR, (1996) Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. J Exp Med 184: 377-386.
60. Miller MF, Mitchell TG, (1991) Killing of Cryptococcus neoformans strains by human neutrophils and monocytes. Infect Immun 59: 24-28.